Skip to Content

Higher Coffee Intake May Reduce Risk for Prostate Cancer

TUESDAY, Jan. 12, 2021 -- Increased coffee consumption is associated with a reduced risk for prostate cancer, according to a review and meta-analysis published online Jan. 11 in BMJ Open.

Xiaonan Chen, from Shengjing Hospital of China Medical University, and colleagues conducted a systematic review with a meta-analysis of cohort studies to examine the association between coffee consumption and the risk for prostate cancer. Data were included from 16 prospective cohort studies with 1,081,586 cohort members and 57,732 cases of prostate cancer.

The researchers observed a significant association between higher coffee consumption and a lower risk for prostate cancer. The pooled relative risk was 0.91 (95 percent confidence interval, 0.84 to 0.98) for the highest versus the lowest category of coffee consumption. A significant linear trend was seen for the association (P = 0.006), with a pooled relative risk of 0.988 (95 percent confidence interval, 0.981 to 0.995) for each increase of one cup of coffee per day. The pooled relative risks were 0.93 (95 percent confidence interval, 0.87 to 0.99), 0.88 (95 percent confidence interval, 0.71 to 1.09), and 0.84 (95 percent confidence interval, 0.66 to 1.08) for localized, advanced, and fatal prostate cancer, respectively.

"This study suggests that increased coffee consumption may be associated with a reduced risk of prostate cancer," the authors write. "If the association is further proved to be a causal effect, men might be encouraged to increase their coffee consumption to potentially decrease the risk of prostate cancer."

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: January 2021

Read this next

Mediterranean Diet Tied to Lower Risk for Prostate Cancer Progression

THURSDAY, Jan. 21, 2021 -- For men with newly diagnosed prostate cancer on active surveillance, adherence to the Mediterranean diet (MedD) is associated with a lower risk for...

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer

MONDAY, Dec. 21, 2020 -- Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food...

Prostate Cancer Pathology Not Worse With Delayed Surgery

FRIDAY, Dec. 11, 2020 -- Among men with clinically localized high-risk prostate adenocarcinoma undergoing radical prostatectomy, surgical delay time (SDT) is not associated with a...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.